Do Vyvanse (lisdexamfetamine) and Lunesta (eszopiclone) affect male fertility?

Direct Answer on Vyvanse and Lunesta Effects on Male Fertility

Based on current evidence, Vyvanse (lisdexamfetamine) shows minimal impact on male fertility with only modest reductions in semen volume, while Lunesta (eszopiclone) demonstrates concerning effects on sperm parameters in animal studies that warrant caution in men actively trying to conceive.

Vyvanse (Lisdexamfetamine) and Male Fertility

Evidence Summary

The most recent and highest-quality evidence comes from a 2026 multi-center retrospective analysis of 2,039 reproductive-age men with ADHD 1. This study provides the strongest data available:

• Semen volume: 8.4% decrease in men taking stimulants (2.70 mL vs 2.95 mL, p=0.01)
• Other parameters preserved: No significant differences in sperm concentration, motility, morphology, or total sperm count
• Clinical significance: The modest volume reduction is unlikely to significantly impair fertility given preserved sperm quality

Guideline Context

The 2024 ADHD in pregnancy guideline 2 notes that lisdexamfetamine is a prodrug converted to dextroamphetamine, with limited published information specifically on male fertility. However, the 2025 EULAR recommendations 3 explicitly state that treatment with lisdexamfetamine can be continued in male patients trying to conceive, as it has not demonstrated clinically relevant impact on offspring outcomes.

The 2021 AUA/ASRM guideline 4 acknowledges that data on specific medications affecting male fertility are limited and recommends consulting specialized databases when concerns arise.

Clinical Recommendation for Vyvanse

Continue Vyvanse in men trying to conceive. The evidence shows:

• Preserved sperm concentration, motility, and morphology
• Only minor semen volume reduction that doesn't compromise total sperm count
• No evidence of adverse offspring outcomes
• Untreated ADHD may pose greater risks to overall health and relationship stability

Lunesta (Eszopiclone) and Male Fertility

FDA Label Evidence

The FDA drug label for Lunesta 5 provides critical preclinical data on fertility:

Animal studies demonstrate significant reproductive toxicity:

• Decreased fertility in both male and female rats at high doses
• Sperm abnormalities: Decreases in sperm number and motility, increases in morphologically abnormal sperm
• No-effect dose: 5 mg/kg in rats (16 times the maximum recommended human dose on mg/m² basis)
• Fertility impairment: No pregnancies occurred when both males and females received the highest dose (45 mg/kg/day in males)

Human Data Gap

There are no published human studies specifically evaluating eszopiclone's effects on male fertility parameters or conception outcomes. This represents a significant evidence gap.

Clinical Recommendation for Lunesta

Consider discontinuing or switching Lunesta in men actively trying to conceive, particularly if:

• Conception attempts have been unsuccessful for >6 months
• Female partner evaluation is normal
• Alternative sleep medications are available

Rationale:

• Animal data show clear dose-dependent effects on sperm parameters
• Lack of human safety data creates uncertainty
• Alternative sleep aids exist (e.g., melatonin, cognitive behavioral therapy for insomnia)
• The drug can be resumed after conception is achieved

Practical Management Algorithm

For Men Taking Vyvanse:

1. Continue medication - no changes needed
2. Counsel that minimal semen volume reduction doesn't impair fertility
3. If conception difficulties arise after 12 months, evaluate both partners per standard infertility workup 4

For Men Taking Lunesta:

1. Assess necessity: Is the medication essential for sleep?
2. Consider alternatives:
   • Non-pharmacologic: Sleep hygiene, cognitive behavioral therapy for insomnia
   • Pharmacologic: Melatonin, trazodone (limited data but no known fertility concerns)
3. If continuing Lunesta: Obtain baseline semen analysis if conception attempts exceed 6 months
4. If switching: Allow 2-3 weeks washout before attempting conception (5 half-lives = ~30 hours × 5 = 6 days, but conservative approach recommended)

Important Caveats

Disease Activity Matters

The 2025 EULAR guideline 3 emphasizes that high disease activity itself may impair male fertility 3. This principle extends to psychiatric conditions - untreated ADHD or insomnia may indirectly affect fertility through:

• Stress and relationship strain
• Poor sleep quality affecting hormonal regulation
• Lifestyle factors associated with untreated conditions

Semen Analysis Considerations

If fertility concerns arise, the 2021 AUA/ASRM guideline 4 recommends:

• Obtain semen analysis as part of initial evaluation
• Abnormalities are most clinically significant when multiple parameters are affected
• Single parameter changes (like isolated volume reduction) are less concerning

Medication Timing

Unlike female reproduction where medication timing relative to conception is critical, male medication exposure primarily affects sperm produced 74-90 days prior (spermatogenesis cycle). However, the 2025 EULAR guideline 3 recommends a conservative 3-month discontinuation before conception attempts for medications with uncertain safety profiles.

Key Takeaway

Vyvanse can be safely continued in men trying to conceive based on reassuring human data showing preserved sperm quality. Lunesta warrants a more cautious approach with consideration of discontinuation or switching to alternatives given concerning animal data and absence of human fertility studies. Both decisions should account for the severity of the underlying condition and availability of effective alternatives.